Virtual DCAT Member Company Announcement Forum
Get the latest developments from across the Bio/Pharmaceutical manufacturing value chain.
The 2021 Virtual DCAT Member Company Announcement Forum is no longer available.
Hear from CEOs and senior executives from DCAT member companies announcing key strategic company developments, including significant manufacturing expansions, mergers and acquisitions (M&A), and post-M&A activities as part of the Virtual DCAT Member Company Announcement Forum.
To access the videos, click the Watch Recorded Announcements button and log into the DCAT member portal.
- If you are a first-time user, click new user to create your profile. Please note, you must use your company email address to be recognized as a DCAT member.
- If the portal says you are already a user, this means you are currently in our database and you will be prompted to reset your password and follow the instructions sent to your email.
- After logging in, you will click DCAT Member Company Announcement Forum at the top of the screen to access the videos which are in alphabetical order by company name.
| Virtual DCAT Member Company Announcement Forum: Announcements From Across the Global Bio/Pharmaceutical Manufacturing Value Chain |
|---|
| Aceto: Gilles Cottier, CEO Acquisition and integration of five companies to add to manufacturing footprint in fine chemicals and life sciences |
| Ajinomoto Bio-Pharma Services: Dr. Mark Cassidy, CEO & President, Ajinomoto Bio-Pharma Services Europe Global expansions in small-molecule API development and manufacturing (including HPAPIs, oligonucleotides and continuous flow chemistry) and fill–finish capacity |
| Asymchem: Elut Hsu, President & Senior Vice President, Business Development Investments in China for two new small-molecule API development and manufacturing facilities |
| Boehringer Ingelheim: Dr. Christian Eckermann, Senior Vice President, Biopharma Austria Update on new EUR 700-M ($829-M) biomanufacturing facility in Vienna |
| Carbogen Amcis: Mark Griffiths, Dishman Carbogen Amcis Group CEO Updates on new small-molecule API manufacturing facility in Switzerland and new formulation and fill–finish facility in France |
| Catalent: Karen Flynn, President, Biologics & Chief Commercial Officer Updates on $380-M-plus manufacturing expansions in biologics, cell & gene therapies, drug products, and cold-chain and cryogenic capabilities |
| Cytiva: Emmanuel Ligner, Danaher Group Executive & President and CEO, Cytiva Acquisition and integration of three companies to support digital bioprocessing, lipid nanoparticle technologies, and small-scale aseptic filling |
| DSM Nutritional Products: Kelsey Achenbach, Global Segment Director, Pharma & Medical Nutrition Formed a new strategic partnership to extend its pharmaceutical offering to include cannabinoid APIs |
| Evonik: Dr. Stefan Randl, Vice President, Research, Development & Innovation, Nutrition & Care, Health Care Update on expansion of small-molecule API manufacturing sites in Germany |
| Frontida BioPharm: Eric Kinzler, Ph.D., Study Director, CAT.one testing services for Abuse-Deterrent Formulations Investment to increase capabilities in abuse-deterrent formulations and development |
| Gerresheimer: Niels Düring, Global Executive Vice President, Primary Packaging Plastics US expansion of pharma plastic packaging production capacity |
| Helsinn Advanced Synthesis: Waldo Mossi, General Manager Lab and manufacturing expansion for HPAPIs |
| LGM Pharma: Prasad Raje, CEO Update on integration of acquisition of a drug-product CDMO |
| Lonza: Christian Dowdeswell, Head of Commercial Development, Small Molecules Global expansions in: (1) small-molecule API development and manufacturing (including HPAPIs); (2) large-scale biomanufacturing (CHF 650 M [$703 M] investment); and (3) cell & gene therapy manufacturing |
| Ortec: Christopher Brotherton, President New GMP chemical manufacturing facility in Ireland |
| PharmaBlock: Jing Li, Ph.D., Senior Vice President Combined $155 M facilities expansion in China for small-molecule API and drug-product manufacturing |
| Polpharma: Shlomo Gang, General Director, Polpharma API Small-molecule API manufacturing expansion (including HPAPIs) and cryogenic capabilities |
| Rondo-Pak: Bob Reilley, President & COO Equipment additions for packaging (folding cartons) |
| Samsung Biologics: Segang Park, Vice President, Team Leader, Engineering Project Management, EPCV Update on new $1.47-Bn biomanufacturing facility in Incheon, South Korea |
| Sanofi US SAIS/EuroAPI: Karl Rotthier, CEO, EuroAPI Update on planned spin-off of new European API manufacturing company |
| Sterling Pharma Solutions: Kevin Cook, CEO Acquisition and integration of a CDMO specializing in HPAPIs and bioconjugation and acquisition of US small-molecule API manufacturing site |
| Stevanato Group: Mauro Stocchi, Chief Business Officer $145-M investment for new US manufacturing facility for containment solutions for aseptic manufacturing |
| Thermo Fisher Scientific: Leon Wyszkowski, President, Commercial Operations, Pharma Services Global expansions in development and manufacturing of biologics, cell & gene therapies, and drug products and expansion of clinical supply-chain capabilities |
| Valsynthese: Mara Guzzetti, Ph.D., Senior Executive Vice President, Fine Chemicals New production hydrogenation facility, upgrade of pilot production, and new kilo laboratory for hazardous chemistry |
| WuXi STA: Yu Lu, Vice President, Business Operations, & Jinling Chen, Senior Vice President, Drug Product Division Global expansions in small-molecule API manufacturing (including HPAPIs, oligonucleotides, peptides) and drug-product manufacturing |